All News

Found 116 articles

• Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders

  6/14/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.

• Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19

  6/11/2021

  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol.

• Adamis Provides Update on ZIMHI™FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021

  6/9/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose

• Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

  6/7/2021

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19

• Adamis Pharmaceuticals Provides Business UpdateNDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19

  6/1/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today provided the following business update.

• Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

  5/28/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021, it received a standard notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC

• 

  FDA Receives Slew of New Drug Applications for Bipolar Disorder, Opioid Disorder and Rare Disease

  5/19/2021

  Several biopharmaceutical companies have submitted NDAs to the U.S. FDA covering treatment indications ranging from an opioid overdose, bipolar disorder and rare disease.

• Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose

  5/17/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for ZIMHI™, a naloxone injection product candidate intended for the treatment of opioid overdose.

• Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call

  5/17/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time.

• Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update

  4/15/2021

  Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT

• Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update

  4/13/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on Thursday, April 15, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2020 as well as provide a business update

• Adamis Pharmaceuticals Provides an Update on ZIMHI™

  4/12/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI™ high-dose naloxone injection product intended for the treatment of opioid overdose.

• Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

  3/15/2021

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls.

• Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19

  2/22/2021

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19.

• Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate

  2/17/2021

  Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™  high dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.

• Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock - Feb 02, 2021

  2/2/2021

  Adamis Pharmaceuticals Corporation, announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $1.11 per share.

• Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Jan 29, 2021

  1/29/2021

  Adamis Pharmaceuticals Corporation announced the pricing of its previously announced underwritten public offering of 40,540,540 shares of its common stock at a public offering price of $1.11 per share, resulting in gross proceeds of approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company.

• Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients

  1/28/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients.

• Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock - Jan 28, 2021

  1/28/2021

  Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

• Adamis Pharmaceuticals Provides Update On Its US Compounding Business

  1/26/2021

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. (USC) subsidiary. Under the terms described in the letter of intent, the buyer would agree to acquire substantially all of the assets of US Compounding in exchange for a total gross consideration that could range from approximately $